GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » ROC (Joel Greenblatt) %

4Front Ventures (4Front Ventures) ROC (Joel Greenblatt) % : 13.64% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is 4Front Ventures ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. 4Front Ventures's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 13.64%.

The historical rank and industry rank for 4Front Ventures's ROC (Joel Greenblatt) % or its related term are showing as below:

FFNTF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -168.11   Med: -15.2   Max: 0.96
Current: -19.64

During the past 13 years, 4Front Ventures's highest ROC (Joel Greenblatt) % was 0.96%. The lowest was -168.11%. And the median was -15.20%.

FFNTF's ROC (Joel Greenblatt) % is ranked worse than
71.92% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 8.03 vs FFNTF: -19.64

4Front Ventures's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


4Front Ventures ROC (Joel Greenblatt) % Historical Data

The historical data trend for 4Front Ventures's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4Front Ventures ROC (Joel Greenblatt) % Chart

4Front Ventures Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163.92 -46.87 -8.91 0.93 -15.30

4Front Ventures Quarterly Data
Jan19 Apr19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.79 -11.77 -13.43 -62.26 13.64

Competitive Comparison of 4Front Ventures's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4Front Ventures's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's ROC (Joel Greenblatt) % falls into.



4Front Ventures ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.208 + 17.162 + 5.454) - (59.802 + 0 + 27.903)
=-60.881

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.682 + 17.087 + 5.02) - (60.063 + 0 + 16.587)
=-50.861

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of 4Front Ventures for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=21.452/( ( (159.505 + max(-60.881, 0)) + (155.06 + max(-50.861, 0)) )/ 2 )
=21.452/( ( 159.505 + 155.06 )/ 2 )
=21.452/157.2825
=13.64 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4Front Ventures  (OTCPK:FFNTF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


4Front Ventures ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


4Front Ventures (4Front Ventures) Business Description

Traded in Other Exchanges
Address
5060 North 40th Street, Suite 120, Phoenix, AZ, USA, 85018
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
Executives
Leonid Gontmakher director, officer: Chief Executive Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick officer: See Remarks C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane director 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano other: Consultant 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati director 28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams officer: Chief Financial Officer 108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt director C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel director 3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut officer: Chief Investment Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham officer: Chief Operating Officer 5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey director ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey officer: Chief Financial Officer C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202